These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3780819)

  • 21. [6 beta-hydroxycortisol: a non-invasive reflection of enzymes of drug metabolism].
    Zhiri A; Wellman-Bednawska M; Siest G
    Pathol Biol (Paris); 1987 Sep; 35(7):1087-93. PubMed ID: 3313218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6 beta-Hydroxycortisol: a noninvasive indicator of enzyme induction.
    Saenger P; Forster E; Kream J
    J Clin Endocrinol Metab; 1981 Mar; 52(3):381-4. PubMed ID: 7462397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study.
    Spahn H; Mutschler E
    Arzneimittelforschung; 1985; 35(1):167-9. PubMed ID: 4039147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A trial of feprazone in ankylosing spondylitis.
    Harkness AJ; Burry HC; Grahame R
    Rheumatol Rehabil; 1977 Aug; 16(3):158-61. PubMed ID: 333540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic mixed function oxidase induction during rifampicin/isoniazid therapy in Indian vegetarians.
    Perry W; Jenkins MV
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):344-8. PubMed ID: 3733284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat.
    James R; Küpfer A; Villeneuve JP; Branch RA
    Drug Metab Dispos; 1981; 9(3):297-302. PubMed ID: 6113944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feprazone compared with indomethacin in the management of rheumatoid arthritis.
    Sturrock R; Isaacs A; Hart FD
    Practitioner; 1975 Jul; 215(1285):94-7. PubMed ID: 1103113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.
    Vital Durand D; Hampden C; Boobis AR; Park BK; Davies DS
    Br J Clin Pharmacol; 1986 Jan; 21(1):1-7. PubMed ID: 3947503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-pressure liquid chromatographic feprazone determination in pharmaceutical formulations.
    Bonora A; Borea PA
    J Pharm Sci; 1979 Jun; 68(6):798-800. PubMed ID: 458589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of methods to study enzyme induction in man.
    Roots I; Saalfrank K; Hildebrandt AG
    Adv Exp Med Biol; 1975; 58(00):485-502. PubMed ID: 239546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind trial of feprazone in osteoarthritis of the hip.
    Bain LS; Lynch MP; Bruce GM
    Curr Med Res Opin; 1977; 4(9):665-9. PubMed ID: 338255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous high-performance liquid chromatographic determination of 6 beta-hydroxycortisol and cortisol in urine with fluorescence detection and its application for estimating hepatic drug-metabolizing enzyme induction.
    Inoue S; Inokuma M; Harada T; Shibutani Y; Yoshitake T; Charles B; Ishida J; Yamaguchi M
    J Chromatogr B Biomed Appl; 1994 Nov; 661(1):15-23. PubMed ID: 7866543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ELISA of 6-beta-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy.
    Zhiri A; Wellman-Bednawska M; Siest G
    Clin Chim Acta; 1986 Jun; 157(3):267-76. PubMed ID: 3731488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic oral delorazepam on in vitro and in vivo hepatic drug-metabolizing enzyme activities in the rat.
    Conti I; Tridico RV; Caccia S
    Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):87-99. PubMed ID: 2109343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some studies of feprazone.
    Haslock I; Burkinshaw L; Berry DJ; Donovan B; Wright V
    Rheumatol Rehabil; 1976 May; 15(2):81-6. PubMed ID: 132695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Miscellaneous rheumatological conditions treated in monitored-release studies with feprazone.
    Harris PG
    J Int Med Res; 1981; 9(4):248-52. PubMed ID: 6973494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man.
    Lecamwasam DS; Franklin C; Turner P
    Br J Clin Pharmacol; 1975 Jun; 2(3):257-62. PubMed ID: 1234506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans.
    Bienvenu T; Rey E; Pons G; d'Athis P; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1991 Nov; 29(11):441-5. PubMed ID: 1800391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal failure complicating feprazone treatment.
    Robertson C; Innes S; Paton J
    Hum Toxicol; 1981; 1(1):71-2. PubMed ID: 6217146
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombocytopenia and haemolytic anaemia due to feprazone.
    Bell PM; Humphrey CA
    Br Med J (Clin Res Ed); 1982 Jan; 284(6308):17. PubMed ID: 6797620
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.